Flexion Therapeutics Inc. (NASDAQ:FLXN) insider Michael D. Clayman purchased 1,667 shares of the firm’s stock in a transaction dated Wednesday, November 23rd. The shares were bought at an average cost of $18.41 per share, with a total value of $30,689.47. Following the transaction, the insider now directly owns 30,721 shares of the company’s stock, valued at approximately $565,573.61. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Flexion Therapeutics Inc. (NASDAQ:FLXN) opened at 18.52 on Friday. The company’s market capitalization is $509.80 million. Flexion Therapeutics Inc. has a 1-year low of $7.56 and a 1-year high of $23.57. The firm has a 50-day moving average price of $19.34 and a 200-day moving average price of $16.58.

Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings results on Monday, November 7th. The specialty pharmaceutical company reported ($0.65) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by $0.02. Equities analysts anticipate that Flexion Therapeutics Inc. will post ($2.76) earnings per share for the current year.

Insider Buying and Selling by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

FLXN has been the topic of several research analyst reports. Lake Street Capital restated a “buy” rating and set a $38.00 price objective on shares of Flexion Therapeutics in a research note on Tuesday, September 6th. Zacks Investment Research cut Flexion Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, September 8th. Cantor Fitzgerald restated a “buy” rating and set a $40.00 price objective on shares of Flexion Therapeutics in a research note on Wednesday, November 2nd. Finally, BCS reduced their price objective on Flexion Therapeutics from $0.65 to $0.02 in a research note on Tuesday, November 8th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Flexion Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $28.28.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Gilder Gagnon Howe & Co. LLC increased its position in shares of Flexion Therapeutics by 27.4% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 4,307,870 shares of the specialty pharmaceutical company’s stock valued at $64,467,000 after buying an additional 927,625 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Flexion Therapeutics by 2.3% in the third quarter. Bank of New York Mellon Corp now owns 1,631,323 shares of the specialty pharmaceutical company’s stock valued at $31,876,000 after buying an additional 37,297 shares in the last quarter. BlackRock Fund Advisors increased its position in shares of Flexion Therapeutics by 33.5% in the third quarter. BlackRock Fund Advisors now owns 1,003,825 shares of the specialty pharmaceutical company’s stock valued at $19,615,000 after buying an additional 251,804 shares in the last quarter. Peregrine Capital Management LLC acquired a new position in shares of Flexion Therapeutics during the third quarter valued at approximately $14,126,000. Finally, TPG Group Holdings SBS Advisors Inc. acquired a new position in shares of Flexion Therapeutics during the second quarter valued at approximately $10,689,000. 68.99% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Michael D. Clayman Purchases 1,667 Shares of Flexion Therapeutics Inc. (FLXN) Stock” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/25/michael-d-clayman-purchases-1667-shares-of-flexion-therapeutics-inc-flxn-stock.html.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain.

5 Day Chart for NASDAQ:FLXN

Receive News & Stock Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related stocks with our FREE daily email newsletter.